Dr Alfred Garfall speaks to ecancer at ASCO 2024 about results from the phase 1/2 MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma.

He reports that in this long-term follow up there has been an improvement on the estimate of the medium duration of response from 20 to 24 months.

Dr Garfall also reports that with this extended follow up and longer dosing no new safety signals were observed.